Abraxane, anyone?? Take a quick look at at the dozen or so drugs that did great in p2 but died in p3. Pancreatic cancer is the 'graveyard,' for drugs. This is no slam dunk. They need to execute a p3 study, show good data AND get it approved. Not easy. Fairly valued for this risk now.